Pharming Group NV:
RUCONEST (rhC1INH) marketed to treat acute Hereditary Angioedema (HAE) attacks with 100% response rate, no relapse, side effects, or plasma risk. Only product with future potential to be approved for both prophylaxis and treatment of attacks of HAE. Profitable, cash flow positive. Announced positive results from a ph2 study of RUCONEST in Contract-induced Nephropathy for patients receiving elective coronary angiography with or without a percutaneous coronary intervention (PCI). Pursuing new delivery formulations and larger indications for RUCONEST/rhC1INH, including 2019 clinical trials in pre-eclampsia and acute kidney injury, and development programs in Pompe and Fabry diseases.
Leiden, 2333 CR
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by